Global Health Press

All Articles

ViVa News — Week 28

Shigella vaccine breakthrough The live-attenuated oral Shigella sonnei vaccine WRSs2 reported 89% efficacy against shigellosis in a phase 2 controlled human infection trial — the highest protection rate ever recorded...

Literature update ViVa week 28-2026

1. Five years after the global TB vaccine roadmap launched, progress is real but painfully thin This narrative review updates the 2021 Global Roadmap for tuberculosis (TB) vaccine research and development, assessing...

ViVa News — Week 27

India — CDSCO digital submission mandate (effective 1 July) From 1 July 2026, India’s Central Drugs Standard Control Organization (CDSCO) requires that all Post-Approval Change applications for human vaccines and...